# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `praxis_study-forensics-032_Claude_Opus_1956e1`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-07T07:58:21.409332+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Opus
**Winner:** Claude Opus — **68.8/100** (margin: 0.0)
**Failure modes:** confidence_mismatch, decorative_uncertainty, missed_key_insight, unsupported_conclusion, unsupported_intermediate_step
**Forensic flags:** 4
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Opus | 30.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 2.4/6 | 5.2/6 | 3.6/8 | 8.0/8 | 0.0/10 | 10.0/10 | **68.8/100** |

## Study Forensics Audit

### Claude Opus

**Classification:** `overclaim` [+] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** none_or_minor, correlation_as_causation

## Reasoning Integrity Audit

### Claude Opus
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 6

## Mechanism Analysis

### Claude Opus
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Opus
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "overclaim"


## Forensic Flags

### Claude Opus

- **[MINOR]** `calibration_gap`: Confidence 0.95 is very high despite listing 3 uncertainties — possible performative calibration
  - `confidence`: "confidence: 0.95"
  - `uncertainties[0]`: "Whether 'cardiovascular protection' could be interpreted as referring only to the biomarker"
- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "overclaim"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "overclaim"


## Evidence Map

### Claude Opus

**Correctness:** 30.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 0.0/8
  - (-) `final_answer`: "overclaim"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 6
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[3]`: "Analyzed the company's claims: 'major breakthrough in cardiovascular protection' and 'transform outcomes'"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 0/6 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[1]`: "Phase 2 trials typically focus on efficacy and safety rather than clinical outcomes"
    _Most substantive assumption_
  - Note: 4/4 substantive assumptions

**Uncertainty Handling:** 2.4/6
  - (+) `uncertainties[0]`: "Whether 'cardiovascular protection' could be interpreted as referring only to the biomarker"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.95"
    _Stated confidence level_
  - (-) `uncertainties[1]`: "The exact wording of what executives said vs. how it was reported"
    _Listed but never addressed in reasoning_
  - (-) `uncertainties[2]`: "Whether the accelerated approval pathway is appropriate for biomarker-based approval"
    _Listed but never addressed in reasoning_
  - Note: 3 uncertainties (3 substantive)
  - Note: 2 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 5.2/6
  - (+) `alternative_hypotheses[1]`: "mechanism_vs_evidence - but the mechanism (LDL reduction) is established in humans, not just animals"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 1/2 include rejection reasoning

**Self Monitoring Quality:** 3.6/8
  - (+) `self_check[2]`: "Checked if I'm being too harsh: No, claiming to transform patient outcomes without measuring any outcomes is a clear ove"
    _Most substantive self-verification step_
  - (-) `self_check[0]`: "Verified that the overclaim is clear: outcome claims without outcome data"
    _Fluff self-check_
  - Note: 4 self-check items
  - Note: Self-check quality: 0 deep, 3 arithmetic, 1 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.72, 272 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Opus

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "overclaim"
  - _Impacts: support_strength_
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "overclaim"
  - _Impacts: support_strength, structural_reasoning_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_

**MINOR:**
- **Confidence Mismatch** `[MEDIUM CONFIDENCE]`: Very high confidence (0.95) on medium task
  - `confidence`: "confidence: 0.95"
  - _Impacts: uncertainty_handling_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'The exact wording of what executives said vs. how it was rep...' is listed but not addressed
  - `uncertainties[1]`: "The exact wording of what executives said vs. how it was reported"
  - _Impacts: uncertainty_handling_
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'Whether the accelerated approval pathway is appropriate for ...' is listed but not addressed
  - `uncertainties[2]`: "Whether the accelerated approval pathway is appropriate for biomarker-based approval"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Opus

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/13 content words)
  - `key_claims[0]`: "Company claims the drug will 'transform outcomes' and provide 'cardiovascular protection' based only"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/4 content words)
  - `key_claims[1]`: "No cardiovascular events were tracked in this trial"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/7 content words)
  - `key_claims[2]`: "The outcome claims exceed the available evidence by several years"
- **[WARN]** `[MEDIUM CONFIDENCE]` `confidence_uncertainty`: Confidence 0.95 is very high despite listing 3 uncertainties — possible performative calibration
  - `confidence`: "confidence: 0.95"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 2 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[1]`: "The exact wording of what executives said vs. how it was reported"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "solid - if the executives had limited claims to LDL reduction only"


## Agent Profiles

### Claude Opus (claude-opus-4-20250514)
**Parse OK:** True | **Latency:** 18108ms

**Final Answer:** overclaim

**Confidence:** 0.95

**Assumptions:**
- The text accurately represents what the company executives said
- Phase 2 trials typically focus on efficacy and safety rather than clinical outcomes
- LDL reduction is an established biomarker but not equivalent to clinical outcomes
- The company is seeking approval based solely on the biomarker data

**Reasoning Steps:**
1. Identified the actual evidence: 65% LDL reduction in a specific patient population over 12 weeks
2. Noted what was measured: only lipid levels and liver safety
3. Noted what was NOT measured: cardiovascular events or clinical outcomes
4. Analyzed the company's claims: 'major breakthrough in cardiovascular protection' and 'transform outcomes'
5. Compared claims to evidence: Company is making outcome claims based only on biomarker data
6. Considered the timeline: outcomes trial won't report for 4+ years, but approval being sought now

**Key Claims:**
- Company claims the drug will 'transform outcomes' and provide 'cardiovascular protection' based only on 12-week biomarker data
- No cardiovascular events were tracked in this trial
- The outcome claims exceed the available evidence by several years

**Alternative Hypotheses:**
- solid - if the executives had limited claims to LDL reduction only
- mechanism_vs_evidence - but the mechanism (LDL reduction) is established in humans, not just animals

**Uncertainties:**
- Whether 'cardiovascular protection' could be interpreted as referring only to the biomarker
- The exact wording of what executives said vs. how it was reported
- Whether the accelerated approval pathway is appropriate for biomarker-based approval

**Self-Verification:**
- Verified that the overclaim is clear: outcome claims without outcome data
- Confirmed this isn't correlation vs. causation: the drug does cause LDL reduction
- Checked if I'm being too harsh: No, claiming to transform patient outcomes without measuring any outcomes is a clear overclaim
- The biomarker-outcome relationship is established but not guaranteed for this specific drug

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 2.4/6 `###.......`
- Alternative Hypothesis Quality: 5.2/6 `########..`
- Self Monitoring Quality: 3.6/8 `####......`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Opus** scored **68.8/100**.

**Best per dimension:**
- Correctness: Claude Opus (30.0/30)
- Support Strength: Claude Opus (0.0/8)
- Structural Reasoning: Claude Opus (4.8/8)
- Assumption Discipline: Claude Opus (4.8/6)
- Uncertainty Handling: Claude Opus (2.4/6)
- Alternative Hypothesis Quality: Claude Opus (5.2/6)
- Self Monitoring Quality: Claude Opus (3.6/8)
- Insight Depth: Claude Opus (8.0/8)
- Mechanism Quality: Claude Opus (0.0/10)
- Communication Efficiency: Claude Opus (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Opus | 18.1s | 68.8/100 | 3.8 |

Failure modes observed: confidence_mismatch, decorative_uncertainty, missed_key_insight, unsupported_conclusion, unsupported_intermediate_step.
